Compare HP Inc (HPQ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Natera Inc. Common Stock — how do they compare? HP Inc trades at $30.42 (market cap $27.47B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.1× HP Inc's market cap, and HP Inc pays a 3.94% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 70 Days and Natera Inc. Common Stock for 0 Days on average.
| HPQ | NTRA | |
|---|---|---|
Market Cap | $27.47B | $57.03B |
Volume | 11,226,290 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $35.48 | $425.64 |
52-Week Low | $18.20 | $179.42 |
Typical Hold Time | 70 Days | 0 Days |
Enterprise Value | $33.64B | $56.18B |
Dividend Yield | 3.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $30.63, up 2.54% today, with a bearish technical signal but strong earnings beats in recent quarters. The company reported $55.3B revenue in 2025 with a net income margin of 4.14%, supported by a low P/E of 11.69. Recent news highlights product launches and AI integration in PCs, though the stock faces headwinds from a forecasted PC market decline in 2027.
The outlook is mixed: valuation metrics appear attractive, and dividend sustainability is supported by cash flow, but risks from PC market softness and negative shareholder equity warrant caution. Analyst consensus is neutral with a $25.75 price target, suggesting limited upside from current levels amid industry challenges.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
